Table 2

Consumer participant data collection framework.

Time pointBaseline6 months12 months
(only in two start-up sites)
Data source
Informed consentxIMeRSe Coordinator and participant
Assessments
 DemographicsxIMeRSe Coordinator and participant
 Cultural identificationxIMeRSe Coordinator and participant
 Support networksxIMeRSe Coordinator and participant
 AHS attendance and usexxxIMeRSe Coordinator and participant
 Clinical history (including medications, hospital admissions and MRPs)xxxIMeRSe Coordinator and participant
health records
 Health resource usexxxMBS, PBS and pathology records
 Care coordinationxxxIMeRSe Coordinator and participant
 Beliefs about Medicines Questionnaire-specific40 xxxIMeRSe Coordinator and participant
 Medication adherence (RAMS40)xxxIMeRSe Coordinator and participant
 Treatment Satisfaction Questionnaire for Medication41 xxxIMeRSe Coordinator and participant
 Health and well-being (GEM43; Kessler–10)39 xxxIMeRSe Coordinator and participant
Medicines review and follow-up
Medicines Talk (Stay Strong Plan)x (+follow up)Pharmacist and participant
 MRPsx (+follow up)GuildCare records (identified by pharmacist)
Medicines Report x (+follow up)GuildCare records (compiled by pharmacist)
My Medicines Plan x (+follow up)GuildCare records (compiled by GP)
Participant feedback about IMeRSe
 Satisfaction and experiencexxIMeRSe Coordinator and participant
Interview with researcher
  • Reported Adherence to Medication Scale40; Growth and Empowerment Measure.43

  • AHS, Aboriginal health service; GP, general practitioner; IMeRSe, Indigenous Medication Review Service; MBS, Medicare Benefits Schedule; MRPs, medication-related problems; PBS, Pharmaceutical Benefits Scheme.